| Title |
Schedule-dependent activity of irinotecan plus BCNU against malignant glioma xenografts
|
|---|---|
| Published in |
Cancer Chemotherapy and Pharmacology, March 2000
|
| DOI | 10.1007/s002800050050 |
| Pubmed ID | |
| Authors |
Henry S. Friedman, Robert C. Castellino, Gertrude B. Elion, Stephen T. Keir, Peter J. Houghton, Stewart P. Johnson, Darell D. Bigner |
| Abstract |
To further evaluate the activity of irinotecan (CPT-11) plus 1,3-bis-(chloroethyl)-1-nitrosourea (BCNU) in the treatment of central nervous system tumor-derived xenografts in athymic nude mice. We report studies evaluating the schedule-dependence of this regimen in the treatment of the malignant glioma xenograft D-54 MG. The combination of BCNU and CPT-11 showed the highest enhancement index (2.0-3.3) when BCNU was given on day 1 and CPT-11 was given on days 1-5 and 8-12. Delay of CPT-11 administration to day 3 or day 5 substantially decreased activity with enhancement indices of 1.6-1.8 and 0.6-1.0, respectively. Delay of BCNU administration to day 8 also reduced the CPT-11 activity with enhancement indices of 1.2-1.4. These results suggest that the presence of a BCNU-induced adduct or possibly crosslink prior to administration of CPT-11 is critical for enhanced activity. Although the mechanism of this enhancement is not currently known, a phase I trial of CPT-11 plus BCNU for adults with recurrent malignant glioma based on these results is in progress. |
Mendeley readers
The data shown below were compiled from readership statistics for 9 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 9 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Lecturer > Senior Lecturer | 2 | 22% |
| Professor | 1 | 11% |
| Student > Ph. D. Student | 1 | 11% |
| Researcher | 1 | 11% |
| Professor > Associate Professor | 1 | 11% |
| Other | 0 | 0% |
| Unknown | 3 | 33% |
| Readers by discipline | Count | As % |
|---|---|---|
| Engineering | 3 | 33% |
| Computer Science | 1 | 11% |
| Unknown | 5 | 56% |
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 28 May 2013.
All research outputs
#8,535,684
of 25,374,917 outputs
Outputs from Cancer Chemotherapy and Pharmacology
#728
of 2,561 outputs
Outputs of similar age
#13,753
of 41,736 outputs
Outputs of similar age from Cancer Chemotherapy and Pharmacology
#2
of 10 outputs
Altmetric has tracked 25,374,917 research outputs across all sources so far. This one is in the 43rd percentile – i.e., 43% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,561 research outputs from this source. They receive a mean Attention Score of 4.5. This one is in the 31st percentile – i.e., 31% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 41,736 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 8th percentile – i.e., 8% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 10 others from the same source and published within six weeks on either side of this one. This one has scored higher than 8 of them.